Hidradenitis Suppurativa

Researchers treated a small cohort with two anti-inflammatory drugs and saw a significant improvement in clinical manifestations of disease.Further data showed the approach safely maintained results.

Evidence supports combined treatments to target the many factors tied to hidradenitis suppurativa.

Misconceptions about hidradenitis suppurativa (HS) prevent dermatologists and other clinicians from properly diagnosing and treating what one expert says is a “crippling disease.”

Many physicians miss diagnosing hidradenitis suppurativa upon first presentation. Recognizing key traits may help physicians diagnose and begin treatment of the disease earlier.

Bacteria responsible for causing skin and soft tissue infections has been found in hidradenitis suppurativa lesions, results of a recent study indicate.

New results from a phase-3 study demonstrating the effect of Humira (adalimumab, AbbVie) in treating moderate-to-severe hidradenitis suppurativa (HS) may lead to worldwide regulatory filings for expanded use of the drug.

Hidradenitis suppurativa (HS) is a challenging disease to treat; however, a better understanding of the disease and continued research has led to more clear-cut therapeutic options, according to an expert who spoke at the North American Clinical Dermatologic Society meeting.

There is a misconception that people with skin of color are not at risk of skin cancer, and dermatologists are responsible for better educating themselves and their patients about this danger, says an expert who spoke at the 72nd Annual Meeting of the American Academy of Dermatology.

A variety of treatments aside from antibiotics have shown some efficacy in managing hidradenitis suppurativa (HS), according to a clinician speaking at the Dermatology Update 2013 meeting.

Adalimumab (Humira, AbbVie) is demonstrating effectiveness in early trials for the treatment of hidradenitis suppurativa, a condition that as of yet has no approved treatment.